Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Reata

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

These Are The 5 Best Stocks Of The Year; Some You May Not Recognize

Reata Pharmaceuticals stock gained 345% this year through Friday and is a top 2023 stock.

Investors Business Daily

Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce

Biogen says it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion. Reata stock surged as Biogen stock gained ground.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Reata Surges 12% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug

Reata CEO Warren Huff says Friedreich's ataxia is "the worst disease." Now, RETA stock investors are watching the long-awaited drug launch.

Investors Business Daily

Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug

Reata Pharmaceuticals won the FDA's blessing to launch its Friedreich's ataxia drug, and RETA stock surged Wednesday.

Investors Business Daily

Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle

Reata took a step closer to launching its highly anticipated Friedreich's ataxia drug on Friday with a new FDA filing, but RETA stock fell.

Investors Business Daily

Top 1% Biotech Reata Crashes On A Delay For Its Most Anticipated Drug

Reata scrapped a chronic kidney disease program and announced a delay for its first commercial product on Wednesday, and RETA stock crashed.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review

The stock market rally, after a big test, rebounded for solid weekly gains, with many leaders flashing buy signals, including Salesforce.

Investors Business Daily

Reata Pharma Stock Almost Triples After Winning 'Coin-Flip' FDA Approval

Reata won Food and Drug Administration approval for its neurological disease treatment and RETA stock almost tripled Wednesday.

Investors Business Daily

Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit

The FDA will decide whether to approve a neurological disease drug from Reata Pharmaceuticals this week, but RETA stock plummeted Monday.

Investors Business Daily

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics’ (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading…

Benzinga

Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review

Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients with Friedreich's ataxia.

Benzinga

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest

U.S. officials will soon examine Reata's request to treat a neurodegenerative condition, and RETA stock continued its two-day climb Friday.

Investors Business Daily

People

Dipanjan BanchurSince

722 stories

Joseph Schwartz

17 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.